A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02444793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1B STUDY OF PF-05082566 IN COMBINATION WITH MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH ADVANCED SOLID TUMORS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MTD of PF-05082566 administered in combination with KW-0761 is estimated (dose finding), one or more expansion cohorts of patients with selected advanced solid tumors (dose-expansion ) will be enrolled to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarkers modulation.
Study identification
- NCT ID
- NCT02444793
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2015 (Actual)
- Primary completion
- Sep 2017 (Actual)
- Completion
- Oct 2017 (Actual)
- Last update posted
- Feb 27, 2019
2015 – 2017
United States locations
- U.S. sites
- 21
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92037-0845 | — |
| UC San Diego Medical Center - La Jolla(Thornton Hospital) | La Jolla | California | 92037 | — |
| University Of California / San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| University of California San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| UC San Diego Medical Center - Hillcrest | San Diego | California | 92103 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Medstar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Henry Ford Hospital Research Pharmacy | Detroit | Michigan | 48202 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| UNC Cancer Hospital Infusion Pharmacy | Chapel Hill | North Carolina | 27514 | — |
| UNC Hospitals, University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599-7600 | — |
| Cleveland Clinic Taussig Cancer Institute | Cleveland | Ohio | 44195 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104 | — |
| Sanford Research | Sioux Falls | South Dakota | 57104 | — |
| Sanford USD Medical Center | Sioux Falls | South Dakota | 57105 | — |
| Tennessee Oncology, PLLC | Gallatin | Tennessee | 37066 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02444793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2019 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02444793 live on ClinicalTrials.gov.